Stage III nonsmall cell lung cancer (NSCLC) comprises about one-third of NSCLC patients
and is very heterogeneous with varying and mostly poor prognosis. It is also called …

Simple Summary Stage III non-small cell lung cancer (NSCLC) is a highly heterogeneous
group of diseases with wide differences in tumor size and in nodal involvement and …

Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that
encompasses patients with resected, potentially resectable and unresectable tumours. To …

Optimal management of patients with locally advanced non–small cell lung cancer remains
challenging in the context of this heterogeneous disease. Despite aggressive therapeutic …

For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up
to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease …

Locally advanced non-small cell lung cancer accounts for one third of non-small cell lung
cancer (NSCLC) at the time of initial diagnosis and presents with a wide range of clinical …

Lung cancer is the second-most commonly diagnosed cancer and the leading cause of
cancer death worldwide. The most common histological type is non-small-cell lung cancer …

Management of stage III non-small cell lung cancer (NSCLC) is very challenging due to
being a group of widely heterogeneous diseases that require multidisciplinary approaches …

The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing
population and introduction of screening for high-risk individuals. Optimal management …

Aims We present the first analysis of the management and outcomes of stage III non-small
cell lung cancer (NSCLC) conducted in England using National Lung Cancer Audit data …